ArticlePharmaceutical research2018
Chitosan Engineered PAMAM Dendrimers as Nanoconstructs for the Enhanced Anti-Cancer Potential and Improved In vivo Brain Pharmacokinetics of Temozolomide.
Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.International journal of nanomedicine · 2019Pooled it
- Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications.International journal of pharmaceutics: X · 2025Review
- Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025Review
- Chitosan and Its Derivatives as Nanocarriers for Drug Delivery.Molecules (Basel, Switzerland) · 2025Review
- Exploring chitosan nanoparticles for enhanced therapy in neurological disorders: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Nose-to-Brain Delivery of Biomimetic Nanoparticles for Glioblastoma Targeted Therapy.ACS applied materials & interfaces · 2025Article
- Advanced Targeted Drug Delivery of Bioactive Agents Fortified with Graft Chitosan in Management of Cancer: A Review.Current medicinal chemistry · 2025Review
- Nanoparticle-Based Approaches in the Diagnosis and Treatment of Brain Tumors.Journal of clinical medicine · 2024Review
- Overcoming the Blood-Brain Barrier: Multifunctional Nanomaterial-Based Strategies for Targeted Drug Delivery in Neurological Disorders.Small science · 2024Article
- Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2024Review
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas.Frontiers in oncology · 2024Review
- Advancements in the Application of Nanomedicine in Alzheimer's Disease: A Therapeutic Perspective.International journal of molecular sciences · 2023Review
- Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs.Life (Basel, Switzerland) · 2023Review
- Review
- Biomimetic Construction of Artificial Selenoenzymes.Biomimetics (Basel, Switzerland) · 2023Review
- Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment.Frontiers in pharmacology · 2023Review
- Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.Theranostics · 2023Review
- Review
- A Review on Increasing the Targeting of PAMAM as Carriers in Glioma Therapy.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo establish a platform for the possibility of effective and safe delivery of Temozolomide (TMZ) to brain via surface engineered (polyamidoamine) PAMAM dendrimer for the treatment of glioblastoma.
methodsThe present study aims to investigate the efficacy of PAMAM-chitosan conjugate based TMZ nanoformulation (PCT) against gliomas in vitro as well as in vivo. The prepared nanoconjugated formulation was characterized by
resultSurface morphology was found as per nanoformulation via size, pdi and zeta potential measurement. PCT was more efficacious in terms of IC
conclusionThe attractive ex vivo cytotoxicity against two glioma cell lines; U-251 and T-98G and phase solubility studies of TMZ revealed remarkable results. In vivo studies of prepared nanoformulation were significant and promising that explored the double concentration of TMZ in brain due to surface functionality of dendrimer. The reported work is novel and non- obvious as none of such approaches using chitosan anchored dendrimer for TMZ delivery has been reported earlier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.